⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 25, 2026Kidney International ReportsOpen Access

WCN26-1861 ATRASENTAN VS PLACEBO IN SUBGROUPS OF PATIENTS FROM EAST ASIA WITH IgA NEPHROPATHY (IgAN): INTERIM DATA FROM THE PHASE III ALIGN TRIAL

Hiddo J.L. Heerspink M Jardine Donald E. Kohan Richard A. Lafayette Adeera Levin Adrian Liew Hong Zhang Suparna Mallik A. R. Patel Yuhan Li Y. Lynn Wang Marion Dahlke Jonathan Barratt

View Full Paper

Ask AI

Bookmark

Share

Implication

Phase III trial demonstrates poor kidney prognosis in East Asian subgroup with IgA nephropathy, highlighting need for early diagnosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Heerspink et al. (2026) studied this question.

synapsesocial.com/papers/69c76fff8bbfbc51511e0597 https://doi.org/10.1016/j.ekir.2026.106179

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1WCN26-1950 A Nomogram for Predicting Renal progression in Adult IgAVN patients Based on the Oxford ClassificationBlinded Clinical Trial · 2026
2WCN26-4847 Multi-Dimensional Research On IgAN Prevention, Diagnosis And TreatmentOriginal Research · 2026
3WCN26-3819 UPDATE TO THE LONG-TERM EFFICACY AND SAFETY OF IPTACOPAN IN C3 GLOMERULOPATHY: 39-MONTH PHASE 2 EXTENSION STUDY DATAEarly-Phase Clinical Trial · 2026
4WCN26-5943 High Diagnostic Yield of Genetic Testing in End-Stage Kidney Disease: Insights from a Large Chinese CohortCohort Study · 2026
5WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL2024